GlassScriptPhysician profile
Christian A Engell
NPI 1831374305
$4,772.87
in general payments reported to CMS, 2019-2025
27 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $388 · 2021: $820 · 2022: $951 · 2023: $782 · 2024: $697 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,156.07 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,000.14 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $488.19 | 2019-2025 | Pifeltro, Verquvo, Dificid |
| La Jolla Pharmaceutical Company | $413.07 | 2021-2025 | Xacduro, Giapreza |
| Theratechnologies INC. | $347.21 | 2019-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Janssen Biotech, INC. | $164.02 | 2020-2022 | |
| Abbvie INC. | $162.77 | 2019-2023 | |
| Shionogi INC | $152.57 | 2022-2025 | Fetroja |
| Allergan, INC. | $152.48 | 2019-2020 | |
| Melinta Therapeutics, LLC | $117.72 | 2021-2024 | Rezzayo, Vabomere, Orbactiv |
| Dynavax Technologies Corporation | $90.87 | 2019-2024 | Heplisav-B |
| Amgen INC. | $84.48 | 2019-2021 | |
| Janssen Products, LP | $69.99 | 2021 | |
| Astellas Pharma US INC | $57.76 | 2023-2025 | Cresemba |
| Pfizer INC. | $56.66 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $53.02 | 2024-2025 | Mytesi |
| Janssen Pharmaceuticals, INC | $48.98 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $27.10 | 2019-2024 | |
| Tetraphase Pharmaceuticals, INC. | $24.98 | 2020 | |
| Aimmune Therapeutics, INC. | $18.41 | 2025 | Vowst |
| Astrazeneca Pharmaceuticals LP | $15.90 | 2022 | |
| Glaxosmithkline, LLC. | $15.00 | 2019 | |
| United Therapeutics Corporation | $14.90 | 2022 | |
| Emd Serono, INC. | $14.78 | 2025 | |
| Novo Nordisk INC | $14.54 | 2020 | |
| Vyera Pharmaceuticals, LLC | $11.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Engell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.